SETD2 and cancer: As G12C is the most common KRAS oncogenic variant in LUAD (Campbell et al., 2016; Wiesweg et al., 2019), we used a recently developed KRASG12C-driven LUAD mouse model (named KcP) (Francis et al., 2024) to test whether the additional loss of SETD2 (named KcP;Setd2) impacted cancer pathogenesis in vivo like it does in a G12D oncogenic mutant background (Figure 1A–C).